Clinical Trials
6 trialsNCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04304144 2025-03-05
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 2 Completed
NCT04115956 2022-03-28
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Oncopeptides AB
Phase 1 Terminated
NCT01318902 2020-04-01
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Takeda
Phase 1 Completed